Status:

RECRUITING

HCC Surveillance: Comparison of Abbreviated Non-contrast MRI and Ultrasound Surveillance in Cirrhotic Patients With Suboptimal Ultrasound Visualisation

Lead Sponsor:

Concord Repatriation General Hospital

Conditions:

Hepatocellular Carcinoma

HCC

Eligibility:

All Genders

20-85 years

Phase:

NA

Brief Summary

All international guidelines recommend 6-monthly ultrasound surveillance for patients at risk for liver cancer (hepatocellular carcinoma or HCC), such as patients with cirrhosis. The aim of surveillan...

Detailed Description

The investigators plan to conduct a prospective study to examine the diagnostic performance of abbreviated non-contrast MRI (aNC-MRI) versus ultrasound, in a select group of cirrhotic patients with po...

Eligibility Criteria

Inclusion

  • Inclusion criteria
  • Patients with cirrhosis (all causes of cirrhosis, except obscure causes such as vascular or congenital fibrosis) AND reduced visualisation of their liver on ultrasound (vB and vC).
  • The criteria of cirrhosis can be obtained with any of the following methods:
  • Histologically by liver biopsy
  • Past signs of decompensated liver disease such as ascites, encephalopathy, varices or bacterial peritonitis
  • Clinically suspicion of cirrhosis PLUS one of the following:
  • Radiological evidence of morphologic changes of the liver and evidence of portal hypertension on US, CT or MRI examinations, including the identification of hepatic surface nodularity, splenomegaly, portal collaterals, varices and ascites
  • Fibroscan (transient elastography) median liver stiffness \>12.5 kPa, the Fibroscan must be performed by an experienced technician and interpreted by the hepatologist
  • Platelet count \<100 (x10\^9/L) with no alternative cause
  • Absence of previous history or current suspicion of HCC - Absence of HCC is defined by liver US, multiphase CT or contrast-enhanced MRI within 6 months prior to surveillance
  • Patient is able to comply with scheduled visits, evaluation plans and other study procedures in the opinion of the investigator
  • Patient is willing to provide written informed consent
  • Exclusion criteria
  • Contraindications to MRI scan (defibrillator, pacemaker, metallic foreign body, severe claustrophobia etc.)
  • Contraindications to gadolinium
  • Age above 85 years old or younger than 20 years old
  • Pregnancy or breast feeding
  • Any other condition which, in the opinion of the Investigator, would make the patient unsuitable for enrolment for the trial or could interfere with the completion of the study

Exclusion

    Key Trial Info

    Start Date :

    January 1 2022

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ESTIMATED

    End Date :

    March 1 2027

    Estimated Enrollment :

    476 Patients enrolled

    Trial Details

    Trial ID

    NCT04455932

    Start Date

    January 1 2022

    End Date

    March 1 2027

    Last Update

    September 8 2021

    Active Locations (10)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 3 (10 locations)

    1

    Royal Prince Alfred Hospital

    Camperdown, New South Wales, Australia, 2050

    2

    Concord Repatriation General Hospital

    Concord, New South Wales, Australia, 2139

    3

    Gosford Hospital

    Gosford, New South Wales, Australia

    4

    Prince of Wales Hospital

    Randwick, New South Wales, Australia, 2031